{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"17.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"A competing risk analysis was conducted to estimate the 2-year cumulative incidence of local tumor progression. Progression followed ablation reporting standards and RECIST v1.1 (mRECIST for HCC).","groups":[{"description":"Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors","id":"OG000","title":"Experimental"},{"description":"Morfeus software was not used during percutaneous thermal ablation of liver tumors","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"The 2-year secondary endpoints were evaluated for the randomized group","reportingStatus":"POSTED","timeFrame":"Time to local tumor progression (LTP) was measured from ablation to earliest LTP or death (competing event). Follow-up imaging continued up to 24 months.","title":"Cumulative Incidence of 2-year Local Tumor Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}